Kriya Therapeutics presented preclinical data at the ARVO Annual Meeting for KRIYA-825, a gene therapy candidate for Geographic Atrophy (GA). KRIYA-825 is an AAV-based therapy delivering a CR2-CR1 fusion protein designed to inhibit complement C3 and C5 activity, key drivers of GA. A Phase 1/2 clinical trial for KRIYA-825 in GA patients is already underway.
This research is crucial because GA, a leading cause of blindness in the elderly, currently lacks effective long-term treatments. Current therapies necessitate frequent intravitreal injections, placing a significant burden on patients. A one-time gene therapy like KRIYA-825 could drastically alter the treatment landscape by offering a potentially durable solution, improving patient compliance and quality of life.
Preclinical data in a mouse model demonstrated that KRIYA-825 preserved retinal thickness in a dose-dependent manner and helped regulate complement protein levels. Studies in non-human primates, utilizing a novel suprachoroidal injection device, confirmed targeted delivery to relevant ocular tissues with minimal systemic exposure. This suggests the therapy effectively reaches the diseased area while minimizing potential side effects.
These findings pave the way for further clinical investigation of KRIYA-825. Positive clinical trial results could lead to a paradigm shift in GA treatment, providing a much-needed, long-term solution for this debilitating condition. This could significantly impact the lives of millions affected by GA and solidify Kriya’s position in the ophthalmology gene therapy field.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
